Cohrem Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
- Paid Up Capital ₹ 1.50 Cr
- Company Age 12 Year, 5 Months
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 4.50 M
About Cohrem Pharmaceutical
Cohrem Pharmaceutical Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 September 2012 and has a history of 12 years and five months. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Corem Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹4.50 M.
Krishnan Perumal and Yamini Krishnan serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232TG2012PTC083037
-
Company No.
083037
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Sep 2012
-
Date of AGM
24 Sep 2015
-
Date of Balance Sheet
31 Mar 2015
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Cohrem Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishnan Perumal
|
Director | 12-Sep-2012 | Current |
|
Yamini Krishnan
|
Director | 12-Sep-2012 | Current |
Financial Performance of Cohrem Pharmaceutical.
Enhance accessibility to Cohrem Pharmaceutical's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cohrem Pharmaceutical?
In 2015, Cohrem Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.45 Cr
₹0
Charges Breakdown by Lending Institutions
- The Karur Vysya Bank Limited : 0.45 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Jul 2013 | The Karur Vysya Bank Limited | ₹4.50 M | Open |
How Many Employees Work at Cohrem Pharmaceutical?
Cohrem Pharmaceutical has a workforce of 45 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cohrem Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cohrem Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
